Dupixent FDA Safety Review: What Regulators Have Found

Last updated: October 2026

The FDA has not found that Dupixent causes lymphoma, but it is looking into the question. In its report covering October to December 2024, the agency listed cutaneous T-cell lymphoma (CTCL) as a potential safety signal for Dupixent and said it was evaluating whether regulatory action is needed. As of October 2026, the U.S. label still has no lymphoma warning. You will also learn how to follow the Dupixent FDA safety review yourself, what CTCL is and which questions to bring to your doctor.

This post explains the Dupixent FDA safety review: how the FDA watches drugs after approval, what it has said about Dupixent so far, and what could happen next. It also explains why these regulatory steps matter to the lawsuits.

How the FDA watches a drug after approval

FDA approval is not the end of safety review. Clinical trials include thousands of people, but some rare side effects only show up after millions use a drug. That is why the FDA keeps tracking drugs once they are on the market.

Key tools include:

• FAERS: The FDA Adverse Event Reporting System collects reports from drug makers, doctors, pharmacists and patients.
• Quarterly signal reports: The FDA publishes lists of potential serious risks it has spotted in FAERS data and is reviewing.
• Label updates: When the evidence supports it, the FDA and the drug maker revise the prescribing information.
• Required studies: The FDA can ask for more research after approval.
• Public communications: For serious concerns, the FDA may issue a Drug Safety Communication to warn doctors and patients.

A report to FAERS alone does not prove a drug caused a problem. Reports can be incomplete, and the illness may have had another cause. Signals are a starting point for review.

Dupixent’s safety history since 2017

Dupixent (dupilumab) was first approved in March 2017 for adults with moderate-to-severe eczema, according to OptumRx’s approval notice. It is made by Regeneron and sold with Sanofi.

Since then, its uses have grown a lot. The current FDA label record, updated in August 2026, lists nine approved uses. They include eczema in patients as young as 6 months, asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis.

Warnings on the label today

The Warnings and Precautions section currently covers:

• Hypersensitivity (allergic) reactions
• Conjunctivitis, keratitis and blepharitis (eye inflammation)
• Eosinophilic conditions
• Risks in asthma or COPD flare-ups and with fast steroid tapering
• New-onset psoriasis
• Joint pain and psoriatic arthritis
• Parasitic (worm) infections
• Vaccination timing

The label’s post-marketing section also lists reports such as facial skin reactions, angioedema and eye problems. Lymphoma is not listed in either section.

The CTCL safety signal

In its October–December 2024 report of potential signals from FAERS, the FDA listed Dupixent with the risk “Cutaneous T-cell lymphoma.” In the action column, it wrote: “FDA is evaluating the need for regulatory action.”

That wording tells us three things:

• The FDA saw enough reports to flag a possible concern.
• It had not concluded that Dupixent causes CTCL.
• It had not yet decided whether to change the label or take other steps.

Why reports alone can’t settle the question

FAERS is useful for spotting patterns, but it has limits. Many side effects are never reported. Others are reported more often after news coverage or lawsuits. Reports may leave out key details, like when symptoms began or what other drugs a person took.

For CTCL, timing is especially tricky. If a patient’s “eczema” was really early lymphoma all along, a report may make it look like the drug came first. That is why the FDA usually looks at other evidence, such as clinical trial data, published studies and the company’s own safety reports, before it decides what to do.

What the research shows

Outside the FDA, researchers have studied the question too. A 2024 study of about 45,000 eczema patients reported higher odds of CTCL in those who took dupilumab, MDedge reported. Other studies have not found a clear increase compared with other treatments. A big open question is whether some patients had early CTCL that looked like eczema before they started the drug.

What could happen next

The FDA has not announced an outcome of its review. In general, when the FDA evaluates a signal like this, possible results include:

• A label change, such as adding CTCL to warnings or to the list of post-marketing reports.
• A request for more study, to better measure the risk.
• A safety communication to doctors and patients.
• No regulatory action, if the review does not support a change.

There is no set deadline for the FDA to finish. Some reviews take months. Others take years. Patients should not stop Dupixent on their own. Dupixent has not been recalled, and your doctor can help you weigh its benefits and risks.

Why the FDA review matters for the lawsuits

Federal Dupixent CTCL lawsuits were combined into MDL No. 3180 in New Jersey in June 2026. The central claim is failure to warn. Plaintiffs argue the companies should have warned about a lymphoma risk. The companies deny the claims.

The FDA’s actions can matter in a few ways:

• The label: The current label is what doctors and patients saw. Plaintiffs will point to what it did not say.
• Timing: When reports reached the companies and the FDA may matter to what the companies knew and when.
• Preemption arguments: Drug makers sometimes argue that federal rules block state-law warning claims. The U.S. Supreme Court addressed this in Wyeth v. Levine (2009) and Merck v. Albrecht (2019). These cases generally allow warning claims unless there is clear evidence the FDA would have rejected the warning.

A future label change would not by itself prove the drug caused anyone’s cancer. The lack of a warning also does not end the question. Courts decide these issues based on the full evidence.

How to report a side effect

Patients and doctors can report side effects directly to the FDA through MedWatch. Reports help the FDA spot patterns. If you had a serious skin change or a lymphoma diagnosis while on Dupixent, you or your doctor can file a report.

It can also help to keep your own records: pharmacy history, biopsy reports and dated photos of your skin.

How to Follow the Dupixent FDA Safety Review Yourself

You do not have to rely on headlines to know where things stand. The FDA posts much of its safety information publicly. Knowing where to look can help you check claims you see online.

The quarterly signal reports

The FDA publishes lists of potential safety signals it has identified, organized by quarter. This is where CTCL first appeared for Dupixent, in the October to December 2024 report. On its reports page, the FDA explains that a drug’s appearance on a quarterly report means the agency has identified a potential safety signal and is evaluating it. It does not mean the FDA has concluded that the drug causes the risk.

The FDA has also said it is building a new Adverse Event Monitoring System (AEMS) to bring together several reporting systems used across FDA-regulated products. So the names and web addresses of these pages may change over time.

The drug label

The prescribing information, often called the label, is the most direct sign of what the FDA and the drug maker have agreed to tell doctors. Any outcome of the Dupixent FDA safety review that changes the label would show up there. The FDA’s public label databases list the date of each label revision.

Safety communications

For serious concerns, the FDA may post a Drug Safety Communication. These are written for both doctors and patients. The FDA lists past communications on its website, so you can check there for anything new about Dupixent.

Tips for reading the news

• Check the date. Older articles may describe a review as “new” long after it began.
• Look for the source. A claim about the Dupixent FDA safety review should point to an FDA page, the label or a court record.
• Watch the wording. “Evaluating” and “potential signal” are not the same as “confirmed risk.”

What the review cannot tell you

The Dupixent FDA safety review is about the drug across all patients. It is meant to decide whether the label or other steps need to change. It will not decide whether Dupixent caused cancer in any one person, and it is not tied to anyone’s legal claim. Those questions are answered in other ways, by doctors and, in lawsuits, by the courts.

What CTCL Is, in Plain Language

Cutaneous T-cell lymphoma is a cancer of white blood cells that shows up in the skin. Because it can look like other skin conditions at first, it is often hard to diagnose.

The most common types

According to the National Cancer Institute’s PDQ summary, mycosis fungoides and Sézary syndrome are the two most common types of cutaneous T-cell lymphoma, which is a type of non-Hodgkin lymphoma. In both, lymphocytes, a kind of white blood cell, become cancerous and affect the skin.

How it can look on the skin

The NCI describes mycosis fungoides as moving through phases. It may start as thin, reddened patches. Over time, these can become raised or hardened areas called plaques. In later stages, tumors may form. Early patches can resemble eczema or psoriasis, which is one reason the timing questions in the Dupixent FDA safety review are so hard to untangle.

How it is diagnosed

A skin biopsy is the main test. A small piece of skin is removed and examined under a microscope. Labs may run more tests on the sample, such as immunophenotyping, flow cytometry or T-cell receptor gene rearrangement testing, to look for abnormal T cells. Sometimes more than one biopsy is needed before a diagnosis is clear.

Why diagnosis can take time

Many people with mycosis fungoides are treated for other skin problems before the right diagnosis is made. Early biopsies may not show clear signs of lymphoma. Doctors may watch the skin over time and repeat biopsies if patches do not respond to treatment. This delay is common and is not always a sign that anyone made a mistake.

Who treats it

CTCL is often managed by dermatologists working with cancer doctors, such as oncologists or hematologists. Some large medical centers have clinics that focus on lymphomas of the skin. Your doctor can tell you whether a referral makes sense for you.

Questions to Ask Your Doctor During the Dupixent FDA Safety Review

The FDA has not told patients to stop Dupixent, and the drug has not been recalled. Still, it is reasonable to talk with your doctor about the open Dupixent FDA safety review. Here are questions that may help guide that conversation.

Prepare before the visit

Write your questions down ahead of time and bring a list of every medicine you have used for your skin, with rough start and stop dates. If you have photos of your skin from before and after starting Dupixent, bring those as well. Clear notes make it easier to have a focused talk about the Dupixent FDA safety review in a short appointment.

About your diagnosis

• How confident are you that my condition is eczema, and not something else?
• Was I ever biopsied before starting Dupixent? If not, would one help now?
• Are there signs that would make you want to check for lymphoma?

About your treatment

• What are the benefits of Dupixent for me, compared with other options?
• What would happen if I paused or changed treatment?
• How often should I come in for skin checks while on this drug?

About changes in your skin

• What kinds of rashes or patches should I report right away?
• Should I take photos of my skin to track changes between visits?
• If my skin stops improving or gets worse, what is the next step?

Do not stop or change Dupixent on your own. Your doctor knows your history and can help you weigh the risks and benefits as the Dupixent FDA safety review moves forward.

Step-by-Step: Reporting a Side Effect to MedWatch

Reports from patients and doctors are part of how the Dupixent FDA safety review began, and they are one of the main ways the FDA spots new safety concerns. If you had a serious skin change or a lymphoma diagnosis while using Dupixent, you or your doctor can file a report. Here is how the process generally works.

1. Gather the basics. Note the drug name, dose, when you started and stopped, the side effect and when it began.
2. Collect key records. A biopsy or pathology report, the name of your diagnosis and the names of your doctors are helpful.
3. Choose how to report. The FDA’s MedWatch program accepts reports through an online form. You can also call 1-800-FDA-1088 to report by phone.
4. Describe what happened in plain words. Include other medicines you took and other health conditions you have.
5. Keep a copy. Save a copy or screenshot of your report and the date you sent it.

You can also ask your doctor to file a report. Doctors may add clinical details that make a report more useful. Drug makers are required to send the FDA reports they receive, too, so you may also choose to contact the manufacturer.

Reporting for a loved one

You can file a report for a family member, such as a child or an elderly parent, or for someone who has died. Use the same steps and include how you are related. If you can, ask the person’s doctor to confirm medical details like the diagnosis and treatment dates.

What happens to your report

Your report goes into the FDA’s adverse event data. The FDA does not usually respond to each report individually. Instead, it looks for patterns across many reports, along with studies and company data. That is how a signal, like the one in the Dupixent FDA safety review, is first flagged.

Key FDA terms

• Adverse event: Any unwanted health problem that happens while using a drug, whether or not the drug caused it.
• Safety signal: Information suggesting a possible new risk that needs more study.
• Prescribing information: The official label written for doctors and pharmacists.
• Warnings and Precautions: The label section that describes serious risks and how to manage them.
• Postmarketing: The period after a drug is approved and sold to the public.
• Patient information: A plain-language leaflet for patients that comes with some drugs. It may change if the label changes.
• Recall: An action to remove a product from the market or correct it. A safety review does not mean a recall is coming.
• Label change: An update to the prescribing information. It can add a new warning, a new reported reaction or new instructions for use.

If you were diagnosed with CTCL or another lymphoma after using Dupixent, a participating law firm may review your situation. Filing deadlines vary by state and claim type.

Dupixent FDA safety review: frequently asked questions

How Direct2Attorney can help

If you used Dupixent and were diagnosed with CTCL or another lymphoma, a participating law firm may review your situation at no cost. Visit our Dupixent lawsuit page to learn more. For court news, see our latest Dupixent lawsuit updates.

The Dupixent FDA safety review is still open. Check back for updates, and talk with your doctor about any new skin changes.

Direct2Attorney is a legal marketing and referral service, not a law firm. This article is general information, not legal advice. Submitting information does not create an attorney-client relationship.